1975 Volume 23 Issue 6 Pages 2151-2157
Amikacin is a new semisynthetic aminoglycoside antibiotic.
The minimal inhibitory concentrations (MIC) of amikacin, gentamicin, DKB, and kanamycin were determined in 30 Pseudomonas aeruginosa strains clinically isolated. The susceptibility to amikacin was as almost same as that of gentamicin but was significantly better than its parent compound, kanamycin. The antibacterial potency of DKB was slightly higher than that of amikacin and gentamicin.
Intramuscular administration of 50 mg amikacin produces a serum concentration of 3.9 μg/ml after 30 minutes, and its half life was 1 hour 15 minutes.
Patients with complicated urinary tract infections were treated with this drug (daily doses 100-400 mg). The clinical responses were excellent in 3 cases, good in 5 cases, and fair in 1 case. We can evaluate this amikacin as one of effective therapeutic drugs for complicated urinary tract infection. In our clinical experiences, any significant change of laboratory findings could not be revealed except increasing eosinophils in 1 case.
